The Uromigos

Episode 265: Brachytherapy with Jeff Michalski 03.10.2023 40:02 ↓

Paper of the month: a randomised trial of brachytherapy vs external beam.

Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial 27.09.2023 29:51 ↓

Jim Catto describes the 17 yr follow up data from this large prostate cancer study.

Episode 263: Toni Choueiri and papillary renal cancer 20.09.2023 36:20 ↓

We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed

Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC. 12.09.2023 30:35 ↓

Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC

Episode 261: part 2 ctDNA in bladder cancer 04.09.2023 40:29 ↓

Matt Galsky completes the discussion on the rapidly moving topic.

Episode 260: Celeste Simon: how to make a career in translation science work. 30.08.2023 26:24 ↓

Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things that went less wells

Episode 259: Cystectomy for bladder cancer 24.08.2023 25:29 ↓

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya

Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1 15.08.2023 46:19 ↓

Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winner) introduces the podcast.

Episode 257: Chana Weinstock from the FDA 07.08.2023 36:22 ↓

Chana discusses her role at the FDA, how it functions and answers questions on topical issues.

Episode 256: ctDNA in urothelial studies. 27.07.2023 37:46 ↓

Mat Galski discusses the past, present and future of ctDNA in this disease.

Episode 255: How to get an academic paper accepted 26.07.2023 30:21 ↓

Walt Stadler gives tips to writing papers and navigating the review process.

Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges 17.07.2023 28:12 ↓

Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' session.

Episode 253: Patients' perspectives on adjuvant and 1st line RCC 13.07.2023 27:02 ↓

Rachel Giles (chair of IKCC) describes her data from patients on these topics in RCC

Episode 252: Talazoparib and its FDA approval in CRPC 04.07.2023 32:13 ↓

Neeraj Agarwal describes the TALAPRO-2 study and relevance of the HRR biomarker in the 2 cohorts presented. A discussion regarding other PARPis and BRCA1/2 occurs

Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion 26.06.2023 50:36 ↓

Meredith Regan and David McDermott try to make sense of it all but are unexpectedly interrupted. PFS2 and TFS are covered along with previously discussed endpoints.

Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1 18.06.2023 30:12 ↓

After the discussion with Mike Atkins, Bob Motzer gives his perspective of the 1st line renal cancer situation .

Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer 18.06.2023 36:49 ↓

Prompted by a question during the oral kidney cancer session at ASCO, Mike Atkins explains his position. Disagreement prevails.

Episode 248: ASCO23 GU highlights 14.06.2023 35:27 ↓

Silke Gillessen joins Brian and Tom for a quick round up.

Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC 05.06.2023 24:27 ↓

Shilpa Gupta discussed these 2 oral abstracts from ASCO

Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer 05.06.2023 27:46 ↓

Toni Choueiri describes the results of this renal cancer trial exploring rechallange with immune therapy

Episode 244: ASCO 2023 PEACE-1 in CRPC 05.06.2023 24:55 ↓

Karim Fizazi described the radiotherapy component of this study.

Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide 05.06.2023 16:16 ↓

ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer 05.06.2023 26:28 ↓

yohann Loriot discusses this practice changing trial

Episode 241: Statistics for clinical trials 01.06.2023 38:10 ↓

Meredith Regan describes how best to interpret KM curves and comparative analysis.

Episode 240: Preview of GU Cancer at ASCO 2023 30.05.2023 27:01 ↓

A look forward to bladder, kidney and prostate cancer sessions at ASCO 2023